Centessa Pharmaceuticals Gains Analyst Confidence Amid Insider Trading Centessa Pharmaceuticals has received a strong "Buy" consensus from analysts, with price targets ranging from $26 to $36. This comes as CEO Saurabh Saha sold $918,060 worth of shares under a pre-established trading plan. The company’s lead drug, ORX750, continues to show promise in addressing sleep disorders, with Phase IIa results expected later this year.12